Bone Marrow Transplant Rejection - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Bone Marrow Transplant Rejection - Pipeline Review, H2 2016

Bone Marrow Transplant Rejection - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Bone Marrow Transplant Rejection - Pipeline Review, H2 2016
Published Aug 31, 2016
427 pages — Published Aug 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Bone Marrow Transplant Rejection - Pipeline Review, H2 2016, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection
- The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects
- The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline

  
Source:
Document ID
GMDHC8428IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents216
  List of Tables152
  List of Figures171
Introduction181
  Global Markets Direct Report Coverage181
Bone Marrow Transplant Rejection Overview191
Therapeutics Development202
  Pipeline Products for Bone Marrow Transplant Rejection Overview201
  Pipeline Products for Bone Marrow Transplant Rejection Comparative Analysis211
Bone Marrow Transplant Rejection Therapeutics under Development by Companies225
Bone Marrow Transplant Rejection Therapeutics under Investigation by Universities/Institutes272
Bone Marrow Transplant Rejection Pipeline Products Glance294
  Late Stage Products291
  Clinical Stage Products301
  Early Stage Products311
  Unknown Stage Products321
Bone Marrow Transplant Rejection Products under Development by Companies336
Bone Marrow Transplant Rejection Products under Investigation by Universities/Institutes392
Bone Marrow Transplant Rejection Companies Involved in Therapeutics Development4166
  AbbVie Inc411
  AbGenomics International, Inc.421
  Actelion Ltd431
  Alexion Pharmaceuticals Inc441
  Amunix Operating Inc.451
  Apceth GmbH &Co. KG461
  arGEN-X BV471
  Athersys, Inc.481
  Bellicum Pharmaceuticals, Inc.491
  Bio-Cancer Treatment International Limited501
  Biogen Inc511
  Boryung Pharmaceutical Co., Ltd.521
  Bristol-Myers Squibb Company531
  Cantex Pharmaceuticals, Inc.541
  Capricor Therapeutics, Inc.551
  Cell Source, Inc.561
  Cell2B S.A.571
  CellECT Bio, Inc.581
  Cleveland BioLabs, Inc.591
  Compugen Ltd.601
  Cynata Therapeutics Limited611
  Cytodyn Inc.621
  Dompe Farmaceutici S.p.A.631
  Dr. Falk Pharma GmbH641
  Escape Therapeutics, Inc.651
  F. Hoffmann-La Roche Ltd.661
  Fate Therapeutics, Inc.671
  Generon (Shanghai) Corporation Ltd.681
  Gilead Sciences, Inc.691
  GlaxoSmithKline Plc701
  Idera Pharmaceuticals, Inc.711
  ImmuNext, Inc.721
  Immunomedics, Inc.731
  Incyte Corporation741
  Kadmon Corporation, LLC751
  Kamada Ltd.761
  Kiadis Pharma N.V.771
  Kymab Limited781
  Kyorin Pharmaceutical Co., Ltd.791
  MacroGenics, Inc.801
  Mallinckrodt Plc811
  Medsenic821
  Mesoblast Limited831
  Millennium Pharmaceuticals Inc841
  Neopharm Ltd.851
  Nohla Therapeutics Inc.861
  Novartis AG871
  OncoImmune, Inc.881
  OSE Immunotherapeutics891
  Pharmicell Co., Ltd.901
  Pluristem Therapeutics Inc.911
  REGiMMUNE Corporation921
  Rigel Pharmaceuticals, Inc.931
  Sarepta Therapeutics, Inc.941
  Seattle Genetics, Inc.951
  Seres Therapeutics, Inc.961
  Sigmoid Pharma Limited971
  Spherium Biomed S.L.981
  Taiga Biotechnologies, Inc.991
  Takeda Pharmaceutical Company Limited1001
  Targazyme, Inc.1011
  Therapix Biosciences Ltd1021
  Tobira Therapeutics, Inc.1031
  Vault Pharma Inc.1041
  Xenikos B.V.1051
  ZIOPHARM Oncology, Inc.1061
Bone Marrow Transplant Rejection Therapeutics Assessment10714
  Assessment by Monotherapy Products1071
  Assessment by Combination Products1081
  Assessment by Target1094
  Assessment by Mechanism of Action1134
  Assessment by Route of Administration1172
  Assessment by Molecule Type1192
Drug Profiles121286
  abatacept Drug Profile1215
  AbGn-168H Drug Profile1262
  AGS-499 Drug Profile1281
  aldesleukin Drug Profile1292
  Alecmestencel-L Drug Profile1311
  alpha-1 proteinase inhibitor (human) Drug Profile1325
  ALXN-1007 Drug Profile1371
  AMX-342 Drug Profile1381
  anti-thymocyte globulin (rabbit) Drug Profile1392
  Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD Drug Profile1411
  Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease Drug Profile1421
  ARGX-115 Drug Profile1431
  arsenic trioxide Drug Profile1441
  ATIR-101 Drug Profile1454
  BCT-200 Drug Profile1491
  begelomab Drug Profile1501
  Biologic to Activate IL-2 for Graft Versus Host Disease Drug Profile1511
  Biologics for Graft Versus Host Disease Drug Profile1521
  bortezomib Drug Profile1538
  BPX-501 Drug Profile1614
  BR-05001 Drug Profile1651
  brentuximab vedotin Drug Profile16624
  budesonide Drug Profile1903
  cannabidiol Drug Profile1931
  CAP-2003 Drug Profile1941
  CBLB-612 Drug Profile1952
  CD-24Fc Drug Profile1971
  Cell Therapy for Graft Versus Host Disease Drug Profile1981
  Cell Therapy for Graft-Versus Host Disease Drug Profile1991
  Cellgram for Graft Versus Host Disease Drug Profile2001
  Cellular Immunotherapy for Acute Graft Versus Host Disease Drug Profile2011
  Cellular Immunotherapy for Autoimmune Diseases and Transplantation Drug Profile2022
  Cellular Immunotherapy for Bone Marrow Transplantation Drug Profile2041
  Cellular Immunotherapy for Graft Versus Host Disease Drug Profile2051
  Cellular Immunotherapy for Graft Versus Host Disease Drug Profile2061
  Cellular Immunotherapy for Graft Versus Host Disease Drug Profile2071
  Cellular Immunotherapy for Graft Versus Host Disease Drug Profile2081
  Cellular Immunotherapy for Graft Versus Host Disease Drug Profile2091
  Cellular Immunotherapy for Graft Versus Host Disease Drug Profile2101
  Cellular Immunotherapy for Graft Versus Host Disease Drug Profile2111
  Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma Drug Profile2121
  cenicriviroc mesylate Drug Profile2137
  CGEN-15001 Drug Profile2203
  CRCBT-080004 Drug Profile2231
  CX-01 Drug Profile2242
  cyclosporine CR + cyclosporine IR Drug Profile2261
  CYP-001 Drug Profile2271
  entospletinib Drug Profile2282
  F-652 Drug Profile2301
  FR-104 Drug Profile2313
  Ha-7 Drug Profile2341
  ibrutinib Drug Profile23525
  ImmuneSafe Drug Profile2601
  ImmuStem Drug Profile2611
  IMO-8400 Drug Profile2626
  IT-603 Drug Profile2681
  IT-901 Drug Profile2691
  itacitinib adipate Drug Profile2703
  KD-025 Drug Profile2734
  KRP-203 Drug Profile2772
  KY-1005 Drug Profile2791
  MAX-16H5 Drug Profile2801
  MesoStem Drug Profile2811
  methoxsalen Drug Profile2822
  MGD-010 Drug Profile2842
  milatuzumab Drug Profile2863
  Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases Drug Profile2892
  MPC-CBE Drug Profile2912
  natalizumab Drug Profile2935
  obinutuzumab Drug Profile2987
  OCU-300 Drug Profile3051
  Oligonucleotide to Inhibit NFAT1 for GVHD Drug Profile3061
  panobinostat Drug Profile3078
  PF-05285401 Drug Profile31511
  PLXR-18 Drug Profile3267
  ponesimod Drug Profile3333
  Preimplantation Factor Drug Profile3361
  PRO-140 Drug Profile3378
  ProTmune Drug Profile3452
  R-348 Drug Profile3472
  Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders Drug Profile3491
  Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis Drug Profile3501
  Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease Drug Profile3511
  remestemcel-L Drug Profile3525
  reparixin Drug Profile3573
  RGI-2001 Drug Profile3602
  RO-2959 Drug Profile3621
  rovalpituzumab tesirine Drug Profile3632
  ruxolitinib phosphate Drug Profile36513
  S-Graft Drug Profile3781
  SER-155 Drug Profile3791
  Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis Drug Profile3801
  Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis Drug Profile3811
  Small Molecules to Inhibit Perforin for Bone Marrow Transplantation Drug Profile3821
  Small Molecules to Inhibit SHIP1 for Oncology and Immunology Drug Profile3831
  Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders Drug Profile3841
  sonidegib phosphate Drug Profile3855
  SP-12008 Drug Profile3901
  SYGN-305 Drug Profile3911
  Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease Drug Profile3921
  T-Guard Drug Profile3932
  TBX-1400 Drug Profile3951
  TM-5509 Drug Profile3961
  TZ-101 Drug Profile3973
  vedolizumab Drug Profile4005
  VPI-101 Drug Profile4051
  ZL-1101 Drug Profile4061
Bone Marrow Transplant Rejection Dormant Projects4076
Bone Marrow Transplant Rejection Discontinued Products4131
Bone Marrow Transplant Rejection Product Development Milestones41412
  Featured News &Press Releases4141
    Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease4141
    Jun 21, 2016: Cynata Prepares for Phase 1 Clinical Trial4141
    Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association4151
    Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers4151
    May 25, 2016: Kamadas Alpha-1 Antitrypsin Now Available to Treat Graft-Versus-Host Disease on myTomorrows Early Access Platform4161
    May 19, 2016: Researchers to Present Additional Data, Including Late-Breaking Results on ALXN1007 in Patients with GI-GVHD at EHA Annual Congress4171
    May 18, 2016: Kiadis Pharma presents multiple sets of data at the International Society for Cellular Therapy 2016 Annual Meeting4181
    Apr 07, 2016: Cynata Reports Compelling Results from Pre-clinical Stem Cell Study in Graft-versus-Host Disease (GvHD)4191
    Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR1014192
    Mar 29, 2016: Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR1014211
    Mar 21, 2016: Kadmon Announces Publication of Data Demonstrating the Potential of ROCK2 Inhibition to Treat Chronic Graft-Versus-Host Disease4211
    Mar 01, 2016: Top-line data from all patients on the primary endpoint of Kiadis Pharma s Phase II trial with ATIR101 selected for oral presentation at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation4221
    Feb 24, 2016: First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee4231
    Feb 22, 2016: Mesoblast s Cell Therapy Increases Survival in Children With Acute Graft Versus Host Disease4241
    Feb 16, 2016: Launch of TEMCELL HS Inj, World s First Mesenchymal Stem Cell Product for GVHD Treatment, and Commencement of Operation of Ultra-Low Cold Chain System4251
Appendix4262
  Methodology4261
  Coverage4261
  Secondary Research4261
  Primary Research4261
  Expert Panel Validation4261
  Contact Us4261
  Disclaimer4271

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Bone Marrow Transplant Rejection - Pipeline Review, H2 2016" Aug 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bone-Marrow-Transplant-Rejection-Pipeline-Review-H2-2016-2088-16511>
  
APA:
Global Markets Direct - Market Research. (2016). Bone Marrow Transplant Rejection - Pipeline Review, H2 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bone-Marrow-Transplant-Rejection-Pipeline-Review-H2-2016-2088-16511>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.